Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia (Q83255595)

From Wikidata

Jump to navigation Jump to search

scientific article published on 21 January 2011

Language	Label	Description	Also known as
English	Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia	scientific article published on 21 January 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252987%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252987%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

phase I clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

S S Farag

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252987%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

L L Wood

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252987%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

J E Schwartz

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252987%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

S Srivastava

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252987%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

R P Nelson

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252987%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

M J Robertson

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252987%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

R Abonour

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252987%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

A Secrest

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252987%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

E Cox

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252987%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

J Baute

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252987%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

C Sullivan

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252987%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

K Kane

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252987%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

D R Jones

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252987%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

21 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252987%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252987%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252987%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252987%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

599-605

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21252987%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective s

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical Experience with Fludarabine in Leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Discovery and development of clofarabine: a nucleoside analogue for treating cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Variable number of tandem repeat (VNTR) markers for human gene mapping

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Clofarabine in adult acute leukemias: clinical success and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.319

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q83255595&oldid=2221362674"